Skip to main content

Explore our strategy and projects
to learn about the future of our company

Results FY 2023 (€/MLN)

1,148

Revenues

375

Adjusted EBITDA

224

Adjusted net profit

209

Free cash flow

Stock price

Discover more

Press releases

27/09/24 - 7:35

Diasorin announces 510(k) submission for LIAISON PLEX® Gram-Negative Blood Culture Assay

09/09/24 - 13:11

Diasorin launches the LIAISON® Streptococcus pneumoniae Ag Assay in all countries accepting the CE Mark
Learn More

Presentations

02/08/24

Diasorin "The Right Test At The Right Time" Presentation
Learn More
Presentations
Calendar

Calendar

Corporate event

View all

LIAISON PLEX® System: the new multiplexing platform of the Group

Diasorin's LIAISON PLEX® System and Respiratory Flex Assay Revolutionize Diagnostics with Flexibility and have Earned FDA Clearance.

Liaison Plex

Keep
in touch

Sign up for our investor alerts
and stay informed
on the latest developments

Privacy Statement *
The Undersigned Confirms That The Information. Provided Pursuant To Leg. Decree No. 196/2003 Has Been Read And Accepted.